Innovative cancer therapies took center stage at the Cancer Prevention and Research Institute of Texas (CPRIT) Oversight Committee meeting on May 21, 2025, as several companies presented groundbreaking advancements in treatment options.

Among the highlights was OR502, a humanized IgG1 monoclonal antibody designed to target tumor-associated macrophages, aiming to reverse immune suppression in cancer patients. Initial funding from CPRIT has already established its safety and antitumor activity, and the new supplemental grant will expand its development into additional solid tumor indications, both as a standalone treatment and in combination with PD-1 checkpoint inhibitors.

InForm AI showcased its RadOnc AI platform, which automates personalized radiation therapy planning. This innovative technology significantly reduces planning times from hours to mere minutes, enhancing efficiency in clinical workflows. The supplemental funding will support further clinical validation and broader integration into treatment systems.

Alterum Therapeutics introduced 4A10, a monoclonal antibody targeting CD127 for aggressive blood cancers. With initial CPRIT funding aiding its preclinical development, the company is now seeking support to advance into a phase 2a study for patients with relapsed refractory B-cell acute lymphoblastic leukemia.

Instapath presented its fluorescence-based imaging platform, LUCI, and the newly cleared NEO scanner, which streamlines the visualization of pathology specimens. The supplemental funding will facilitate further development and clinical evaluation of the NEO platform.

Rapamycin Holdings reported promising results for eRAPA, an improved formulation of rapamycin for familial adenomatous polyposis (FAP), a genetic condition that can lead to colorectal cancer. With FDA Fast Track designation achieved, the company is expanding its phase 3 trial to strengthen registration efforts.

Prana's METERCore device, designed for minimally invasive lung cancer excisions, is set to expand its first-in-human study with additional funding, ensuring timely regulatory submissions and commercialization.

Lastly, Resilience is making strides in differentiated cell therapies, focusing on manufacturing platforms for advanced cancer treatments. Their recent achievements include optimizing clinical workflows and accelerating therapeutic development.

The meeting underscored CPRIT's commitment to advancing innovative cancer treatments, with significant funding opportunities aimed at enhancing patient outcomes and expanding therapeutic options in Texas.